| scholarly article | Q13442814 |
| P2093 | author name string | Oakhill A | |
| Bu'Lock FA | |||
| Martin RP | |||
| Mott MG | |||
| Gabriel HM | |||
| P2860 | cites work | Risk factors for doxorubicin-induced congestive heart failure | Q28328220 |
| Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine | Q28366936 | ||
| Reduction of daunomycin toxicity by razoxane | Q36045398 | ||
| Cardiac toxicity 4 to 20 years after completing anthracycline therapy | Q41142694 | ||
| Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast | Q41482029 | ||
| Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response | Q67590955 | ||
| Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles | Q69936656 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 185-188 | |
| P577 | publication date | 1993-08-01 | |
| P1433 | published in | British Heart Journal | Q26842435 |
| P1476 | title | Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease | |
| P478 | volume | 70 |
| Q36116430 | Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management |
| Q33613628 | Anthracyclines and the heart |
| Q41711763 | Anthracyclines in haematology: preclinical studies, toxicity and delivery systems |
| Q33625243 | Anthracyclines: cardiotoxicity and its prevention |
| Q36914391 | Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncolog |
| Q35849444 | Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis. |
| Q39264529 | Cardioprotective Effect of Grape Seed Extract on Chronic Doxorubicin-Induced Cardiac Toxicity in Wistar Rats. |
| Q36174517 | Cardiotoxicity of cancer chemotherapy: implications for children |
| Q33704056 | Cardiotoxicity of cancer therapy |
| Q42605936 | Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). |
| Q77355928 | Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography |
| Q28379015 | Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention |
| Q40828883 | Dexrazoxane (ICRF-187). |
| Q36126521 | Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy |
| Q35583768 | Dexrazoxane as a cardioprotectant in children receiving anthracyclines |
| Q37569911 | Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database |
| Q42538949 | Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy |
| Q52888199 | Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women. |
| Q33588565 | Drug-induced heart failure |
| Q34800157 | Early identification of anthracycline cardiomyopathy: possibilities and implications |
| Q33455575 | Effect of dexrazoxane and amifostine on the vertebral bone quality of Doxorubicin treated male rats |
| Q36099606 | Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients |
| Q89735701 | Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective |
| Q46611256 | Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up |
| Q46619189 | Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients |
| Q42764756 | Preventing the cardiotoxicity of anthracyclines by dexrazoxane |
| Q34120033 | The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity. |
| Q28301317 | Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity |
Search more.